Retrograde portal vein flow and transarterial chemoembolization in patients with hepatocellular carcinoma – a case–control study

References

• El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011;365:1118–1127.
   PubMed Web of Science ®Google Scholar
• Iranpour P, Lall C, Houshyar R, et al. Altered Doppler flow patterns in cirrhosis patients: an overview. Ultrasonography. 2016;35:3–12.
   PubMed Web of Science ®Google Scholar
• Tsochatzis EA, Bosch J, Burroughs AK. Liver cirrhosis. Lancet. 2014;383:1749–1761.
   PubMed Web of Science ®Google Scholar
• Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.
   PubMed Web of Science ®Google Scholar
• Llovet JM, Real MI, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359:1734–1739.
   PubMed Web of Science ®Google Scholar
• Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002;35:1164–1171.
   PubMed Web of Science ®Google Scholar
• Park JW, Chen M, Colombo M, et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. Liver Int. 2015;35:2155–2166.
   PubMed Web of Science ®Google Scholar
• Malek NP, Schmidt S, Huber P, et al. The diagnosis and treatment of hepatocellular carcinoma. Dtsch Arztebl Int. 2014;111:101–106.
   PubMed Web of Science ®Google Scholar
• Lencioni R, de Baere T, Soulen MC, et al. Lipiodol transarterial chemoembolization for hepatocellular carcinoma: a systematic review of efficacy and safety data. Hepatology. 2016;64:106–116.
   PubMed Web of Science ®Google Scholar
• Kothary N, Weintraub JL, Susman J, et al. Transarterial chemoembolization for primary hepatocellular carcinoma in patients at high risk. J Vasc Interv Radiol. 2007;18:1517–1526. quiz 1527.
   PubMed Web of Science ®Google Scholar
• Spahr L, Becker C, Pugin J, et al. Acute portal hemodynamics and cytokine changesfollowing selective transarterial chemoembolization in patients with cirrhosis and hepatocellular carcinoma. Med Sci Monit. 2003;9:CR383–CR388.
   PubMedGoogle Scholar
• Ho YJ, Chang MB, Lin YH, et al. Quantitative portal vein velocity of liver cancer patients with transcatheter arterial chemoembolization on angiography. ScientificWorldJournal. 2012;2012:830531.
   PubMed Web of Science ®Google Scholar
• Luo J, Guo RP, Lai EC, et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a prospective comparative study. Ann Surg Oncol. 2011;18:413–420.
   PubMed Web of Science ®Google Scholar
• Chung GE, Lee JH, Kim HY, et al. Transarterial chemoembolization can be safely performed in patients with hepatocellular carcinoma invading the main portal vein and may improve the overall survival. Radiology. 2011;258:627–634.
   PubMed Web of Science ®Google Scholar
• Xue TC, Xie XY, Zhang L, et al. Transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: a meta-analysis. BMC Gastroenterol. 2013;13:60.
   PubMed Web of Science ®Google Scholar
• Pinter M, Hucke F, Graziadei I, et al. Advanced-stage hepatocellular carcinoma: transarterial chemoembolization versus sorafenib. Radiology. 2012;263:590–599.
   PubMed Web of Science ®Google Scholar
• Kirstein MM, Schweitzer N, Ay N, et al. Experience from a real-life cohort: outcome of patients with hepatocellular carcinoma following transarterial chemoembolization. Scand J Gastroenterol. 2016;52:116–124.
   PubMed Web of Science ®Google Scholar
• Berzigotti A, Piscaglia F, Education E, et al. Ultrasound in portal hypertension–part 2– and EFSUMB recommendations for the performance and reporting of ultrasound examinations in portal hypertension. Ultraschall in Med. 2012;33:8–32. quiz 30-31.
   PubMed Web of Science ®Google Scholar
• Johnson PJ, Berhane S, Kagebayashi C, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-cased approach-the ALBI grade. JCO. 2015;33:550–558.
   PubMed Web of Science ®Google Scholar
• Waked I, Berhane S, Toyoda H, et al. Transarterial chemo-embolisation of hepatocellular carcinoma: impact of liver function and vascular invasion. Br J Cancer. 2017;116:448--454.
   PubMed Web of Science ®Google Scholar
• Berzigotti A, Rossi V, Tiani C, et al. Prognostic value of a single HVPG measurement and Doppler-ultrasound evaluation in patients with cirrhosis and portal hypertension. J Gastroenterol. 2011;46:687–695.
   PubMed Web of Science ®Google Scholar
• European Association For The Study Of The L, European Organisation For R, Treatment Of C. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56:908–943.
   PubMed Web of Science ®Google Scholar
• Sieghart W, Hucke F, Pinter M, et al. The ART of decision making: retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma. Hepatology. 2013;57:2261–2273.
   PubMed Web of Science ®Google Scholar
• Adhoute X, Penaranda G, Naude S, et al. Retreatment with TACE: the ABCR SCORE, an aid to the decision-making process. J Hepatol. 2015;62:855–862.
   PubMed Web of Science ®Google Scholar
• Elia C, Venon WD, Stradella D, et al. Transcatheter arterial chemoembolization for hepatocellular carcinoma in cirrhosis: influence on portal hypertension. Eur J Gastroenterol Hepatol. 2011;23:573–577.
   PubMed Web of Science ®Google Scholar
• El Sherbiny W, AbdelRahman A, Diasty M, et al. Changes in Doppler parameters of portal pressure after interventional management of hepatocellular carcinoma. Abdom Radiol. 2016;41:1532–1538.
   PubMed Web of Science ®Google Scholar
• Kirchhoff TD, Rudolph KL, Layer G, et al. Chemoocclusion vs chemoperfusion for treatment of advanced hepatocellular carcinoma: a randomised trial. Eur J Surg Oncol. 2006;32:201–207.
   PubMed Web of Science ®Google Scholar